On March 29, Yingli Pharmaceuticals announced that its PI3Kδ inhibitor linperlisib (YY-20394) for the treatment of relapsed/refractory follicular lymphoma phase 2 registration clinical trial was initially completed.
Linperlisib is an oral PI3Kδ inhibitor developed by Yingli Pharmaceutical.
This announcement is a single-arm, open, multi-center phase 2 clinical trial (YY-20394-002), which aims to evaluate the effectiveness and safety of linperlisib in the treatment of patients with relapsed and/or refractory follicular lymphoma.
Phase 2 registration clinical data showed that linperlisib showed significant clinical benefit in subjects with relapsed/refractory follicular lymphoma: Among 89 evaluable patients with relapsed/refractory follicular lymphoma, linperlisib reached An objective remission rate of more than 80%, and a disease control rate of more than 95%.
In addition, from the analysis of statistical results, oral administration of linperlisib is safe, controllable and well tolerated.
Yingli Pharmaceutical plans to communicate with multiple regulatory authorities around the world on the results of the Phase 2 clinical trial of linperlisib for the treatment of relapsed/refractory follicular lymphoma, and will gradually announce the data.
▲Linperlisib molecular structure (picture source: reference )